Over time, RRMS will progress to secondary progressive MS for most people, which is characterised by progressive disability. For this technology appraisal, the committee evaluated cladribine only for ...

Thousands of NHS patients in England with multiple sclerosis (MS) will soon be offered a "take at home" tablet to manage their condition, sparing them hospital visits for injections or infusions.

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by ...

Medscape Medical News, March 13, 2025 NICE Expands Cladribine Access for MS Patients NICE has recommended cladribine for adults with relapsing-remitting multiple sclerosis, expanding access to the ...